The Role of Protein Elongation Factor eEF1A2 in Breast Cancer
Abstract
The overall goal of the project is to explore the role of protein elongation factor eEFlA2 in breast tumour development and to determine whether eEF1A2 is a useful breast cancer prognostic factor. Elongation factor eEF1A2 is one of two members of the eEF1A family of proteins (eEF1A1 and eEF1A2) that bind amino-acylated tRNA and facilitate their recruitment to the ribosome during protein translation elongation[l]. eEFlA proteins have other functions and can also induce actin [2] and tubulin [3] cytoskeleton rearrangements. Inactivation of the mouse eEF1A2 homolog, Eef1a2, leads to immunodeficiency and neural/muscular defects and death by 30 days of age [4, 5]. We had previously identified eEF1A2 as an ovarian cancer oncogene that could transform human and mouse cells[6], but its role in breast cancer was unknown. We also proposed to test the idea that eEF1A2 could modulate sensitivity to cisplatin and taxol and whether eEFlA2-inactivation could be used as a treatment for breast cancer. In addition, we hoped to understand the mechanism by which eEF1A2 regulates cell and oncogenesis. We have made progress in the following areas: 1. The prognostic significance of eEF1A2 in breast cancer. 2. The ability of eEF1A2 to enhance the growth properties of malignant breast cells. 3. Generation of eEF 1 A2 transgenic mice. 4. The role of eEF1A2 in regulating the cytotoxicity of anti-cancer agents. 5. eEF1A2 inactivation as an anti-cancer treatment. 6. Modulation of cell adhesion and migration by eEF1A2.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2005
- Accession Number
- ADA446358
Entities
People
- Jonathan M. Lee